ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

arlocabtagene autoleucel

Also written as “BMS-986393”, “Arlocabtagene Autoleucel” and “CC-95266”.

Its studies are mostly in Multiple Myeloma, led by Bristol-Myers Squibb.

Drug pageArlocabtagene autoleucel: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Sep 24, 20243 company-led studies, 2 open or runningNext primary completion: Dec 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb32 open or runningphase 3since Sep 24, 2024Dec 14, 2020Dec 30, 2027phase 3 · NCT06615479
  • Named in Bristol-Myers Squibb’s own pipeline as arlo-cel, phase 3, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 14, 2020First study: phase 1 study in Multiple MyelomaFirst studyNCT04674813 · 130 enrolled · United States
  2. Feb 28, 2024Phase 2 study in Multiple MyelomaNCT06297226 · 230 planned · United States, Australia, Canada and more
  3. Feb 29, 2024Named arlocabtagene autoleucelINNProposed as its International Nonproprietary Name in WHO's List 130 · before, BMS-986393, CC-95266
  4. Sep 24, 2024Phase 3 study in RecurrenceNCT06615479 · 440 planned · United States, Argentina, Australia and more

Ahead

  1. Dec 30, 2027Primary completion: phase 3 study in RecurrenceNCT06615479

TargetBeta

“A preparation of autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) human G-protein coupled receptor family C group 5 member D (GPRC5D), with potential immunostimulating and antineoplastic activities. Upon leukapheresis…”NCIt, read by Claude

Other programs on GPRC5D

ProgramCompanyFurthest phaseStudies
ramantamigJohnson & Johnsonphase 38
GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003ruleInnovent Biologicsphase 34
QLS4131ruleQilu Pharmaceuticalphase 33
QLS32015ruleQilu Pharmaceuticalphase 32
vemzatatug vedotinAstraZenecaphase 21
MBS314 for Injectionrulebeijing-mabworks-biotech-co-ltdphase 21
REGN17372ruleRegeneron Pharmaceuticalsphase 21
Anti-GPRC5D Monoclonal Antibody SAR446523Sanofiphase 11
tunlucabtagene autoleucelBristol-Myers Squibbphase 11
TQB2029Sino Biopharmaceuticalphase 11

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06615479Recurrence · United States, Argentina, Australia and more3RecruitingDec 30, 2027440
NCT06297226Multiple Myeloma · United States, Australia, Canada and more2RecruitingJul 31, 2026230
NCT04674813Multiple Myeloma · United States1CompletedDec 22, 2025130

How it is read

Names in the registry

  • “BMS-986393”, 1 entry
  • “Arlocabtagene Autoleucel”, 1 entry
  • “CC-95266”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.